Weikang Pharmaceutical announced that the company recently received the approval notice for the supplementary application of Jinqiancao Capsule issued by the National Medical Products Administration. This approval involves changes to the safety-related content in the drug's package insert and the excipients in the formulation, and also approves the addition of gelatin hollow capsules from Zhejiang Weikang Oujiang Capsule Co., Ltd. for use in this drug. In the first quarter of 2026, Weikang Pharmaceutical achieved revenue of 69.66 million yuan and a net profit attributable to the parent company of 1.74 million yuan.
Wecome Pharmaceutical Co LtdApproval of supplementary application for Jinqiancao Capsule by NMPA, a regulatory approval that may enhance product safety and marketability.
